MAP3K6

Across TCGA pan-cancer cohorts, MAP3K6 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of MAP3K6’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where MAP3K6 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAP3K6 is over-expressed in tumor, although a few such as BRCA and LUAD show the opposite, repressed pattern.

THCA, KIRC, and LIHC are the cancer types where MAP3K6 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP3K6 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	+1.154	<.001	11	view →
KIRC	Female	All	+0.958	<.001	11	view →
LIHC	All	II,III,IV	+0.844	<.001	6	view →
BRCA	All	II,III,IV	−0.644	<.001	6	view →
PAAD	All	All	+0.957	.003	4	view →
LUAD	All	All	−0.448	<.001	4	view →
CHOL	All	All	+1.783	<.001	3	view →
UCEC	All	All	−0.483	.044	2	view →
BLCA	All	IV	−0.879	.028	1	view →
KIRP	Female	All	+0.468	.025	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

MAP3K6–THCA

Open the THCA breakdown →